Sign in →

Test Code CSPCF Plasma Cell Proliferative Disorder, Pre-Analysis Cell Sorting, Bone Marrow


Specimen Required


Only orderable as a reflex. See PCPDS / Plasma Cell Proliferative Disorder, High Risk with Reflex Probes, Diagnostic FISH Evaluation, Bone Marrow

 

Specimen Type: Bone marrow

Preferred: Yellow top (ACD solution A or B)

Acceptable: Lavender top (EDTA) or green top (heparin)

Specimen Volume: 4 mL

Collection Instructions:

1. Invert several times to mix bone marrow

2. Send bone marrow specimen in original tube. Do not aliquot.


Useful For

Aiding in the diagnosis of new cases of multiple myeloma or other plasma cell proliferative disorders

 

Sorting plasma cells for fluorescence in situ hybridization analysis

Method Name

Only orderable as a reflex. See PCPDS / Plasma Cell Proliferative Disorder, High Risk with Reflex Probes, Diagnostic FISH Evaluation, Bone Marrow

 

Flow Cytometric Cell Selection

Reporting Name

PCPDS Pre-Analysis Cell Sorting, BM

Specimen Type

Bone Marrow

Specimen Minimum Volume

2 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Bone Marrow Ambient (preferred) 4 days
  Refrigerated  4 days

Reference Values

Only orderable as a reflex. See PCPDS / Plasma Cell Proliferative Disorder, High Risk with Reflex Probes, Diagnostic FISH Evaluation, Bone Marrow

 

An interpretive report will be provided.

Interpretation

Correlation with clinical, histopathologic and additional laboratory findings is required for final interpretation of these results. The final interpretation of results for clinical management of the patient is the responsibility of the managing physician.

Clinical Reference

1 Swerdlow S, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. IARC Press; 2017

2. Kumar SK, Rajkumar SV. The multiple myelomas-current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15(7):409-421. doi: 10.1038/s41571-018-0018-y

3. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015 May 14;125(20):3069-3075. doi:10.1182/blood-2014-09-568899

4. Muchtar E, Dispenzieri A, Kumar S et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017;31(7);1562-1569. doi: 10.1038/leu.2016.369

5. Lakshman A, Paul S, Rajkumar SV et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. 2018;32(8);1811-1815. doi: 10.1038/s41375-018-0030-3

6. Bochtler T, Hegenbart U, Kunz C, et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016;128(4):594-602. doi:10.1182/blood-2015-10-7

7. Treatment guidelines: multiple myeloma. mSMART 3.0. Accessed October 27, 2023. Available at www.msmart.org/mm-treatment-guidelines

Day(s) Performed

Specimens processed: Monday through Sunday

Results reported: Monday through Friday

Report Available

1 to 7 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

88184-Flow Cytometry; first cell surface, cytoplasmic or nuclear marker

88185 x 5-Flow Cytometry, additional cell surface, cytoplasmic or nuclear marker (each)

LOINC Code Information

Result ID Test Result Name Result LOINC Value
607684 PCPDS Pre-Analysis Cell Sort No LOINC Needed
607689 Final Diagnosis No LOINC Needed